Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

16P - Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells


06 Mar 2023


Cocktail & Poster Display session


Luiz Gustavo Chuffa


Annals of Oncology (2023) 8 (1suppl_2): 100900-100900. 10.1016/esmoop/esmoop100900


L.G. Chuffa1, H.S. Silveira1, R.C. Cesário1, R.A. Vígaro1, F. Guimarães2, F.R. Seiva3

Author affiliations

  • 1 Structural And Functional Biology, UNESP - Instituto de Biociencias (IBB) - Campus de Botucatu, 18618-970 - Botucatu/BR
  • 2 Hospital Da Mulher Prof. Dr. José Aristodemo Pinotti -caism, Unicamp - Universidade Estadual de Campinas, 13083-881 - Campinas/BR
  • 3 Biological Sciences, UENP, 86360-000 - Bandeirantes/BR


This content is available to ESMO members and event participants.

Abstract 16P


Ovarian cancer (OC) is the second gynecological malignancy among women and presents high rates of recurrence associated with chemoresistance. Tumor cells adjust their energy metabolism in favor of their rapid progression. Melatonin (Mel), a hormone produced and secreted by the pineal gland during darkness, has obvious anti-tumor activities. Therefore, we investigated the mechanistic role of Mel on energy metabolism in human OC cells (SKOV-3 and CAISMOV24 cells), with special focus on glycolytic metabolism in addition to cell signaling molecules.


Cell lines were treated with Mel at concentrations of 3.4 μM for SKOV-3 and 7 μM for CAISMOV24 based on the cell cytotoxicity (CC50) for 24 h; a luzindole-treated group was used to test the influence of melatonin receptors, MT1 and MT2. Protein levels of glycolytic enzymes were analyzed by western blot and kinase levels were measured by multiplex assay.


Melatonin levels dropped by half in the OC cells. We observed a significant decline in the levels of HIF-1α, G6PDH, GAPDH, LDH, and PDH in OC cells treated with melatonin regardless of the presence of luzindole, thus proving its receptor-independent actions; conversely, the luzindole-exposed groups had an upregulation of these proteins. In regard to kinases signaling, SKOV-3 cells treated with melatonin had a reduction in the concentration of CREB, JNK, NF-kB, p-38, ERK1/2, Akt, p70s6k, STAT3, and STAT5, all of them associated with tumor growth, metastasis, and recruitment of oncostatic components. In the CAISMOV24 cells, these molecules were reduced after the combination of melatonin with luzindole.


These findings showed that melatonin potentially regulates energy-related processes in OC cells, thereby favoring the reversal of the Warburg effect, in addition to attenuating cell signaling involved with tumor progression.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institute of Biosciences of Botucatu.


CAPES, FAPESP (grant number: 2021/12971-7), CNPq (304108/2020-0).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.